Home
ArticlesArticlesLabman and TMRW partner for CryoRobot to revolutionize IVF labs with secure, automated cryogenic storage and RFID-enabled sample tracking. The partnership brings safety and efficiency gains, setting a new standard for fertility clinics worldwide.
TMRW Life Sciences and Labman have developed a next-generation IVF specimen storage and retrieval system that integrates biometric scanning, a custom cryogenic tank, and end-to-end digital tracking to improve safety, efficiency, and scalability in embryology labs. The CE‑marked CryoRobot Select aligns with FDA requirements, multiple ISO standards, and GDPR, and is now embedded in TMRW’s product pipeline for global deployment.
Conventional IVF workflows are vulnerable to mishandling, inefficient tracking, and suboptimal storage conditions that compound risk as frozen inventories grow, prompting an automation-first redesign of cryostorage management. The CryoRobot Select was engineered to directly address these gaps by reducing manual touchpoints, standardizing conditions, and creating a verifiable digital chain of custody at the sample level.
The platform pairs purpose-built hardware, a tailored cryogenic storage tank, and a robotic picker with software-enabled specimen identification using RFID tags unique to each patient sample. Embryologists gain global, real-time visibility and auditability over eggs and embryos, supported by biometric access control and continuous system checks to maintain optimal temperature and handling conditions.
In testing and verification, the technology demonstrated safer, more controlled handling environments for eggs and embryos stored within the TMRW ecosystem, providing added assurance to clinics and patients. Reported operational benefits include substantial reductions in storage and retrieval cycle times, consistent with automation-driven efficiencies that minimize potential points of failure compared with manual systems.
The CryoRobot Select received the EU CE Mark following FDA clearance, meeting rigorous safety and performance standards under European Medical Device Regulations and aligning with multiple ISO frameworks. The system’s data practices are designed to comply with GDPR and to support EMR integration and audit-ready traceability across the IVF laboratory workflow.
TMRW’s device engineering leadership highlights that replacing the earlier-generation automation with CryoRobot Select enables expansion into more clinics and markets thanks to a smaller footprint, shorter cycle times, and reduced user handling. The collaboration emphasized a risk-based development process to protect both the patient and specimen at every step of storage and retrieval.
This collaboration shows how specialized automation engineering and fertility technology can be combined to harden critical lab processes while simplifying daily operations for embryologists. As demand for cryopreservation scales, clinics adopting automated storage with digital specimen management are positioned to reduce errors, improve throughput, and strengthen patient confidence in chain-of-custody and safety controls.
Labman and TMRW partner for CryoRobot to establish a new benchmark for IVF cryostorage: high-volume capacity, precise tracking, and robust compliance in a compact, deployable form factor for global labs. By elevating consistency and accountability in the most sensitive stages of IVF, Labman and TMRW partner for CryoRobot to align clinical operations with the scale and expectations of modern fertility care. Ultimately, Labman and TMRW partner for CryoRobot to make specimen management safer and more efficient while reinforcing trust through demonstrable, digital traceability.
The shift in reproductive medicine toward "restorative" approaches. By targeting the molecular causes of infertility, such as oocyte aneuploidy, new biotechnologies are moving beyond embryo selection to directly improve IVF success rates and address the root biological causes of age-related fertility decline.
The differences between Mini IVF and traditional IVF, focusing on success rates, medication dosages, and cost-effectiveness. Learn how minimal stimulation protocols prioritize egg quality to offer a less invasive path to parenthood for specific patient profiles.
Clinical evidence increasingly demonstrates that emotional stress or grief reduces the chances of IVF success through sophisticated biochemical pathways that directly influence reproductive physiology. This relationship extends far beyond simple correlations, revealing profound mechanistic connections between psychological distress and the delicate orchestration of hormonal events essential for successful conception.
The mental health of men undergoing IVF impacts the process, highlighting emotional stress, clinical evidence, and strategies to overcome challenges for better reproductive outcomes.
The unique challenges of In Vitro Fertilization (IVF) for women over 40 and highlights various solutions, including egg donation and personalised treatment plans. It emphasises that advancements in reproductive medicine are empowering many women seeking In Vitro Fertilization (IVF) for women over 40 to fulfill their dreams of parenthood.
In Vitro Fertilization (IVF) insurance and financial options available to individuals and couples, helping to alleviate the financial burden of fertility treatments. It highlights various resources, including state mandates, employer-sponsored coverage, financing plans, and grants, that can make IVF more accessible.
Donor egg IVF uses eggs from a healthy donor, fertilized in a lab, and transferred to the intended mother's uterus. This fertility treatment helps women with poor egg quality, premature menopause, genetic concerns, or failed IVF cycles achieve pregnancy. Success rates range from 50-75%, offering hope for parenthood.
